TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline to Week 12 in Fasting Triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline to Week 12 in Fasting Low-density Lipoprotein Cholesterol (LDL-CHO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Charcot Marie-Tooth Pediatric Scale (CMTPedS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Charcot-Marie-Tooth Neuropathy Score second version (CMTNSv2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Charcot Marie-Tooth Functional Outcome Measure (CMT-FOM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CMT Health Index (CMTHI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Magnetic Resonance Imaging (MRI) of the calf muscles without contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Polysomnographic sleep architecture measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular Distance-corrected Near Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Manifest Cylinder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Gene Expression Patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for diagnosing heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 90-day complication rate and severity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in mean maximum carotid intimal medial thickness (IMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ethanol Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak anti-Xa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Clearance of Hepatitis B surface antigen (HBsAg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical attachment level changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choroidal thickness measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major vascular access site complications
Endpoint domain: Adverse events/effects
Primary endpoint: Blood-pressure measurement skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Hamilton Depression Rating Scale (HDRS-21) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risk of bronchopulmonary dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Acceptable TPV Hemodynamic Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of post-infarction heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Predictive value of COPD questionnaires
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Successfully Swallowed Study Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve 0 to Last (AUC 0-last) of Sitagliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Knee Joint Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in The Timed Up & Go Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-viral cytokine levels in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-viral cytokine profiles within sputum samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-viral cytokine profiles within nasal lavage samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression of inflammatory gene expression in upper respiratory epithelial airway cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacodynamics (PD) Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC and Cmax of warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Protein intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Local Reactions Within 10 Days After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Systemic Events Within 7 Days After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Stringent Complete Response (sCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stop Signal Task (SST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Alcohol approach/avoidance bias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Hamilton Depression Scale (HAMD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: time to the first occurrence of stroke, non-CNS systemic embolism, myocardial infarction or vascular death
Endpoint domain: Mortality/survival
Primary endpoint: Time to optimum visualization of the vocal cords
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity and specificity of probe melting curves technology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cord Blood Engraftment by Day 100
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of Substance Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SARS-CoV-2 viral load level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety and tolerability of MRx0518 in combination with pembrolizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical benefit of MRx0518 in combination with pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Internal DHA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative Incidence of Non Relapse Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Clinical Deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological classification of spinal cord injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: VAS (visual analog scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first analgesic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Success level
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in BPRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PANSS negative subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of ECV (fetus turned from Breech to cephalic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: lidocaine efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variance of glucose metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to insert an IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Subjective Stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Recent Life Stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Magnetic Resonance Imaging (MRI) of therapeutic current flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barefoot plantar pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients developing a foot ulcer
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Survival at 2 Years
Endpoint domain: Mortality/survival
Primary endpoint: Urticarial Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Improvement in Silvermann Anderson Retraction Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gluco-dynamic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Performance longevity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of TlimQ (min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of TAS-102
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Viral Load Set-point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum change in hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Comparison of misoprostol drug levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of cytokine and chemokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Determination of immune cell activation state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants diagnosed with preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Changes in cardiac function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of URTI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total scores of AIMS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dietary Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean head penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in number of minor surgical procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diarrhea days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: infarction volume in brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MOSSAS-3HF score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of Heavy Drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Drinks per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 90-day emergency room visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: 90-day readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participant's Subjective Rating for Lens Handling
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participants Subjective Rating for Lens Comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Eye Care Practitioner's Objective Assessment of Binocular High Contrast Distance Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke volume and stroke volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in naïve B Cells From Baseline to Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 24 and Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Implant Migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Success rate in cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in diabetes quality of care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inherited predisposition to breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response Rate (Major and Complete Cytogenetic Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in the six minute walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Subjects That Experienced Treatment-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Inflammatory profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum plasma concentration of papaverine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of children completing home oral immunotherapy protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Heal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in presence of subclinical cardiovascular disease burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in severity of subclinical cardiovascular disease burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Headache Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waist Circumference (WC) decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follicular Cycle Total Behavioral Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Follicular Cycle Total Physical Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Luteal Cycle Total Behavioral Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Luteal Cycle Total Physical Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of AXER-204 in Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax in Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the PDQ-39 summary index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ratio of AUClast and Cmax for Cytochrome P450 substrates at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of AUClast and Cmax for Cytochrome P450 substrates after 4 weeks of dupilumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sodium Conductance by Nasal Potential Difference (NPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of collisions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects with Serum Urate Levels <6.0 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants with Dose Limiting Adverse Events (DLAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Suicidal Ideation and Behavior Using the Columbia Suicide Severity Rating Scale (C-SSRS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proliferation by Ki67
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Apoptosis marker (TUNEL assay)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Percent of Dose Recovered in Urine and Feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) from time 0 to time of the last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Peak Plasma Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum phosphate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: OT Participation scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Post-Procedural Hemorrhage reduction of ≥ 85% in hemorrhage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of mortality at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of left ventricular mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nonfatal acute myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recommended Safe Dose of Moxetumomab Pasudotox-tdfk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Safe Dose of Rituximab/Ruxience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of exercise-induced bronchoconstriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clearance of high risk HPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in decisional conflict over time
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in decisional regret over time
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in satisfaction with decision over time
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in anxiety over time
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in depression over time
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Stress over time
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: tumor cell necrosis rate (TCNR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes